In This Episode We Discuss: Clinical Trial Innovation
What you’ll get out of this episode:
- Introduction of Colin Weller: Vice President and GM of Evidence Platform at Medable, Colin Weller discusses his role in advancing clinical research technology to streamline drug approvals.
- Challenges in Drug Development: Weller details the stagnant pace of drug development, highlighting the industry’s need for innovation to improve efficiency and reduce costs.
- Medable’s Ambitious Goals: Aiming to increase the number of drugs approved annually by tenfold through advanced SAS technology and AI, setting a new industry standard.
- Innovations in Clinical Trials: Medable has already cut study startup times by 50%, utilizing AI and automation to overhaul traditional processes.
- Future of Digital Clinical Trials: Weller predicts significant advancements in decentralized and digital trials, enhancing patient accessibility and data quality.
Watch
Listen
Read More on Clinical Trial Innovation
Transforming Drug Development with Advanced Technology
In a detailed conversation on the “Bio Breakthroughs” podcast, hosted by Jared S. Taylor, Colin Weller, Vice President and General Manager at Medable, shared his extensive background in clinical research and his current role in transforming the clinical trial landscape. Weller emphasized the inefficiencies in traditional drug development processes, which have remained largely unchanged for decades, costing the industry billions annually and taking up to 12 years to bring a drug to market.
Medable’s Strategy for Change
Medable, under Weller’s leadership, is not just about technological advancement but fundamentally changing the paradigm of clinical trials. With a North Star vision of drastically increasing the number of therapies delivered to patients each year, Medable leverages technology at every step. Weller discussed their approach of “one day study startup, one day study recruitment, and one year study conduct,” which contrasts sharply with the current 10-12 year norm.
The Role of AI and Digital Transformation
AI plays a pivotal role in Medable’s strategy, especially in areas like study configuration and patient recruitment. The shift towards more decentralized and digital trials, accelerated by the pandemic, has been supported by changes in regulatory perspectives and advances in technology, allowing for greater data collection through digital means and enhancing patient experiences.
Looking Ahead: The Future of Clinical Trials
In the next few years, Weller sees an acceleration in the adoption of digital health technologies in clinical trials. The integration of AI will continue to optimize the clinical trial process, not only in drug discovery but across operational aspects, potentially transforming the way clinical trials are designed and executed.
Colin Weller’s insights underline a crucial pivot in healthcare technology, with Medable at the forefront, aiming to revolutionize the industry by improving the speed, efficiency, and patient involvement in clinical trials.
WORD FROM OUR SPONSORS:
Our sponsor for this episode are Sage Growth Partners.
Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media – @sagegrowthpartners
To learn more about our guest and their innovative addiction treatments:
– Guest’s LinkedIn – Company LinkedIn – Website –
Also, be sure to follow Slice of Healthcare on our social channels:
– Website – LinkedIn – Twitter – YouTube – Newsletter –
